small molecule glp-1 receptor agonist PDB-101: of the Month: Agonists Design, Synthesis, and Pharmacological Evaluation

It is projected that the rise of these drugs will be driven by increased penetration in primary care facilities, availability via pharmacies, obesity treatment through telehealth, and higher consumer demand for more accessible forms of treatment

affect whitebrown fat metabolism and other mechanisms (55, 57)

Medications ship directly, and check-ins are virtual, making the program accessible anywhere

1 This equates to about 29.1 million people who could be visiting community pharmacies for diabetes medications and supplies

doi: 10.1152/ajpendo.1999.276.6.E1049 62 GellingRWCoyDHPedersonRAWheelerMBHinkeSKwanTet al